In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Novo Nordisk A/S

https://www.novonordisk.com/

Latest From Novo Nordisk A/S

Novo Nordisk Q2 Preview: Focus On Rybelsus, Ozempic And Payors

Novo Nordisk’s 6 August Q2 update will be scrutinized for clues on its plans for semaglutide in obesity, sales data for diabetes drugs Rybelsus and Ozempic, and likely M&A.

Clinical Trials M & A

Lilly Points To Six-Month Growth Instead Of Pandemic Impacted Q2

Lilly argues the overall trend is positive, although the second quarter was down. Trial successes with Verzenio, Trulicity, Jardiance and mirikizumab offer additional growth potential.

Sales & Earnings Business Strategies

Bluebird Seeks EU Fast-Track Review For Lenti-D Gene Therapy

Bluebird bio is planning to file its EU marketing application for Lenti-D this year, before it files for approval in the US in mid-2021.

Drug Review Europe

Concerns About Eye Toxicity Could Limit GSK’s Myeloma Drug Potential

Company told more measures needed to limit damage to patients' eyes caused by antibody drug conjugate.

Commercial Companies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Carbometrics
    • Neose Technologies, Inc.
    • Novo Holdings A/S
    • Novo Nordisk Pharmaceuticals, Inc.
    • Pharmaero Aps
    • Xellia Pharmaceuticals ApS
    • Ziylo Ltd
UsernamePublicRestriction

Register